Response to "Rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?".
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
Massimo
M
Franchini
University of Padua, Padua, Italy.
Carlo
C
Mengoli
D005169:Factor VIII / Q000009:adverse effects*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans
D005169:Factor VIII